Table 7.

Characteristics of the participants in the qualitative interview

	ICI patients N = 12
Age (years), mean ± SD (Mitchell et al.)	61.5 ± 11.7 (40–83)
Type of cancer
Malignant melanoma	3 (25%)
NSCLC	2 (17%)
Urogenital cancer	2 (17%)
Head and neck cancer	3 (25%)
Colon cancer	1 (8%)
Malignant germ cell tumour	1 (8%)
Metastasis	12 (100%)
Monotherapy with PD-1 inhibitor
Nivolumab	8 (67%)
Pembrolizumab	4 (33%)
Time since first administration of ICI (months), mean ± SD (Mitchell et al.)	12.7 ± 9.2 (1–27)